Cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in advanced gastrointestinal cancer

A. Scanni, M. Tomirotti, A. Margulis, M. Biraghi, G. Curtarelli

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The effectiveness of the cyclophosphamide + methotrexate + 5-fluorouracil schedule (CMF) in 28 patients with advanced gastrointestinal cancer has been studied. No complete remission was obtained; partial remission and objective improvement constituted 56%. The median response period is calculated at a minimum of 12 months, without significant differences between the group of patients previously subjected to palliative canalization surgery and the group of patients not subjected to this operation. The overall median survival time is 10.8 months. On the basis of the data given, the authors conclude by stressing that the CMF combination should be studied more fully in relation to its use in gastrointestinal forms of cancer.

Original languageEnglish
Pages (from-to)111-117
Number of pages7
JournalTumori
Volume65
Issue number1
Publication statusPublished - 1979

Fingerprint

Gastrointestinal Neoplasms
Methotrexate
Fluorouracil
Cyclophosphamide
Palliative Care
Appointments and Schedules
Survival

ASJC Scopus subject areas

  • Cancer Research

Cite this

Scanni, A., Tomirotti, M., Margulis, A., Biraghi, M., & Curtarelli, G. (1979). Cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in advanced gastrointestinal cancer. Tumori, 65(1), 111-117.

Cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in advanced gastrointestinal cancer. / Scanni, A.; Tomirotti, M.; Margulis, A.; Biraghi, M.; Curtarelli, G.

In: Tumori, Vol. 65, No. 1, 1979, p. 111-117.

Research output: Contribution to journalArticle

Scanni, A, Tomirotti, M, Margulis, A, Biraghi, M & Curtarelli, G 1979, 'Cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in advanced gastrointestinal cancer', Tumori, vol. 65, no. 1, pp. 111-117.
Scanni A, Tomirotti M, Margulis A, Biraghi M, Curtarelli G. Cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in advanced gastrointestinal cancer. Tumori. 1979;65(1):111-117.
Scanni, A. ; Tomirotti, M. ; Margulis, A. ; Biraghi, M. ; Curtarelli, G. / Cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in advanced gastrointestinal cancer. In: Tumori. 1979 ; Vol. 65, No. 1. pp. 111-117.
@article{a786aba4233544b18d651dd87cd14860,
title = "Cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in advanced gastrointestinal cancer",
abstract = "The effectiveness of the cyclophosphamide + methotrexate + 5-fluorouracil schedule (CMF) in 28 patients with advanced gastrointestinal cancer has been studied. No complete remission was obtained; partial remission and objective improvement constituted 56{\%}. The median response period is calculated at a minimum of 12 months, without significant differences between the group of patients previously subjected to palliative canalization surgery and the group of patients not subjected to this operation. The overall median survival time is 10.8 months. On the basis of the data given, the authors conclude by stressing that the CMF combination should be studied more fully in relation to its use in gastrointestinal forms of cancer.",
author = "A. Scanni and M. Tomirotti and A. Margulis and M. Biraghi and G. Curtarelli",
year = "1979",
language = "English",
volume = "65",
pages = "111--117",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in advanced gastrointestinal cancer

AU - Scanni, A.

AU - Tomirotti, M.

AU - Margulis, A.

AU - Biraghi, M.

AU - Curtarelli, G.

PY - 1979

Y1 - 1979

N2 - The effectiveness of the cyclophosphamide + methotrexate + 5-fluorouracil schedule (CMF) in 28 patients with advanced gastrointestinal cancer has been studied. No complete remission was obtained; partial remission and objective improvement constituted 56%. The median response period is calculated at a minimum of 12 months, without significant differences between the group of patients previously subjected to palliative canalization surgery and the group of patients not subjected to this operation. The overall median survival time is 10.8 months. On the basis of the data given, the authors conclude by stressing that the CMF combination should be studied more fully in relation to its use in gastrointestinal forms of cancer.

AB - The effectiveness of the cyclophosphamide + methotrexate + 5-fluorouracil schedule (CMF) in 28 patients with advanced gastrointestinal cancer has been studied. No complete remission was obtained; partial remission and objective improvement constituted 56%. The median response period is calculated at a minimum of 12 months, without significant differences between the group of patients previously subjected to palliative canalization surgery and the group of patients not subjected to this operation. The overall median survival time is 10.8 months. On the basis of the data given, the authors conclude by stressing that the CMF combination should be studied more fully in relation to its use in gastrointestinal forms of cancer.

UR - http://www.scopus.com/inward/record.url?scp=0018768646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018768646&partnerID=8YFLogxK

M3 - Article

C2 - 87046

AN - SCOPUS:0018768646

VL - 65

SP - 111

EP - 117

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 1

ER -